Currently, there are two types of chemotherapy (platinum-containing drugs and taxane) and two types of targeted treatments which are poly ADP-ribose polymerase (PARP) inhibitors (PARPi) and vascular endothelial growth factor (VEGF) inhibitors (VEGFi) for ovarian cancer, depending on their anti-tumor mechanism or material [1]. This evidence concerns the gene VEGFA and ovarian cancer.